Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

  • The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions 
  • CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively
  • CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021
  • At the end of 2021, CNS gained approval from swissethics to initiate trial sites in Switzerland for the global trial of Berubicin
  • Virtual event participation can be found on the CNS website under “Events”

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently participated in the 2022 Virtual Growth Conference presented by the Maxim Group LLC and hosted by M-Vest from March 28-30. CEO of CNS, John Climaco, represented the company, sharing the corporate presentation and participating in a fireside chat that was moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group. The CNS corporate presentation was made available on-demand to those attending the virtual summit. 

The conference is a platform for investors to hear from company executives from a vast array of sectors, including biotech, clean energy, electric vehicles (“EV”), financial services, fintech, REITS, gaming, entertainment, healthcare, healthcare IT, and more…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.